Cargando…

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data

Detalles Bibliográficos
Autores principales:	De Benedetti, F, Brunner, H, Ruperto, N, Schneider, R, Woo, P, Burgos-Vargas, R, Dolezalova, P, Joos, R, Wulffraat, N, Zuber, Z, Zulian, F, Allen, R, Brown, D, Chaitow, J, Pardeo, M, Espada, G, Flato, B, Gerloni, V, Horneff, G, Wright, S, Kenwright, A, Lovell, D, Martini, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194518/ http://dx.doi.org/10.1186/1546-0096-9-S1-P164

Ejemplares similares

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)
por: De Benedetti, F, et al.
Publicado: (2013)

PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial
por: Malattia, C, et al.
Publicado: (2013)

PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study
por: Mirjafari, H, et al.
Publicado: (2013)

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
por: De Benedetti, F, et al.
Publicado: (2013)

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
por: Quartier, P, et al.
Publicado: (2013)

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
por: Nirmala, N, et al.
Publicado: (2013)

Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
por: Ravelli, A, et al.
Publicado: (2014)

Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
por: Ravelli, A, et al.
Publicado: (2014)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
por: De Benedetti, F, et al.
Publicado: (2014)

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
por: De Benedetti, F, et al.
Publicado: (2013)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
por: Livermore, P, et al.
Publicado: (2008)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
por: Yamaguchi, Ken-ichi, et al.
Publicado: (2012)

Hemoculture and Polymerase Chain Reaction Using Primers TCZ1/TCZ2 for the Diagnosis of Canine and Feline Trypanosomiasis
por: Eloy, Luciano José, et al.
Publicado: (2012)

P02-029 - CAPS or SJIA
por: Alekseeva, E, et al.
Publicado: (2013)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

Tocilizumab (TCZ) Decreases Angiogenesis in Rheumatoid Arthritis Through Its Regulatory Effect on miR-146a-5p and EMMPRIN/CD147
por: Zisman, Devy, et al.
Publicado: (2021)

Mitochondrial and oxidative stress genes are differentially expressed in neutrophils of sJIA patients treated with tocilizumab: a pilot microarray study
por: Omoyinmi, Ebun, et al.
Publicado: (2016)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2014)

Share – Workpackage 4: addressing the need for health care for paediatric rheumatic diseases throughout europe
por: Dolezalova, Pavla, et al.
Publicado: (2014)

Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial
por: Brunner, Hermine I., et al.
Publicado: (2021)

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
por: Malattia, Clara, et al.
Publicado: (2020)

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
por: Brunner, Hermine I, et al.
Publicado: (2015)

13.4 High frequency of CNS involvement in linear scleroderma of the face
por: Parolin, M, et al.
Publicado: (2008)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity
por: Kudela, Holger, et al.
Publicado: (2019)

PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate
por: Ruperto, N, et al.
Publicado: (2013)

Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
por: Kumar, Sharath, et al.
Publicado: (2012)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
por: Bullement, Ash, et al.
Publicado: (2021)

S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH
por: Holzinger, D, et al.
Publicado: (2015)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Physical Examination Tool for Swollen and Tender Lower Limb Joints in Juvenile Idiopathic Arthritis: A Pilot Diagnostic Accuracy Study
por: Fellas, Antoni, et al.
Publicado: (2022)

Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Show Differences in Autoantibody Signatures Based on Disease Activity
por: Krainer, Julie, et al.
Publicado: (2023)

7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis
por: Ruperto, N, et al.
Publicado: (2008)

High Induction of IL-6 Secretion From hUCMSCs Optimize the Potential of hUCMSCs and TCZ as Therapy for COVID-19-Related ARDS
por: Lo, Huei-Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dn72puhog4pijrfbc1v6pu8nqa